← board
CLDI
distress 8/10 · high distress / dilution risk$0.10-6%today-99% from 52w high
Lead: solid tumors
Revenue
pre-revenue
Liquidity
$7M
Runway
0.4 yrs
Shares 1y
+464%
Price & events
-90.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-5.6%
1D
-13.7%
1W
-35.8%
1M
-54.5%
3M
-90.2%
6M
-98.9%
1Y
-99.5%
2Y
—
5Y
-100.0%
All
Overview
- Market Cap
- $1.93M
- Enterprise Value
- $-4.32M
- Volume
- 48.68M
- 52 Week Range
- $0.10 – $9.26
- Total Shares
- 19.31M
- Float Shares
- 19.00M
- Short %
- 22.52%
- % Held by Insiders
- 1.87%
- % Held by Institutions
- 10.40%
- RVOL
- 8.69x
- Beta
- 1.30
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- by end of 2026Guided 40%regulatory submissionFiled (NDA/BLA)CLD-401 · IND filing for CLD-401 expected by end of 2026SEC 8-K
- 2026 AACR-IO conferenceconferencedata presentationsecondaryCLD-401 · Presented data on in situ T-cell engagers using RedTail platformSEC 8-K
- early 2025trial initiationsecondaryPhase 1/2CLD-101 · Phase 1b/2 clinical trial of CLD-101 in newly diagnosed high-grade glioma to commence at Northwestern UniversitySEC 8-K
- 2024-11-12fda agreementCLD-101 · FDA cleared Northwestern University's IND for CLD-101 (NeuroNova) for Phase 1b/2 trial in high-grade gliomaSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 19,311,625 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — solid tumors
Recent news
- 2026-07-21Calidi Gains on Company Update - Baystreet.ca
- 2026-07-21Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers - GlobeNewswire
- 2026-07-21Calidi Cut G&A by About $1M; Targets First Dose in Q1 2027 - Stock Titan
- 2026-07-20Calidi Biotherapeutics to Effect 1-for-16 Reverse Stock Split - marketscreener.com
- 2026-07-20Calidi shareholders will get one share for every 16 held - Stock Titan
- 2026-07-20Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026 - Yahoo Finance Singapore
- 2026-07-17Calidi Biotherapeutics Plans Relocation Through New Lease Agreements - TipRanks
- 2026-07-16Calidi Biotherapeutics Signs 44-Month Lease at 5580 Morehouse Drive, San Diego for New Corporate Headquarters - Minichart
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.